Fabian Tollens1, Niklas Westhoff2, Jost von Hardenberg2, Sven Clausen3, Michael Ehmann3, Frank G Zöllner4, Anne Adlung4, Dominik F Bauer4, Stefan O Schoenberg1, Dominik Nörenberg5. 1. Klinik für Radiologie und Nuklearmedizin, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland. 2. Klinik für Urologie und Urochirurgie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland. 3. Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland. 4. Computerunterstützte Klinische Medizin, Mannheimer Institut für Intelligente Systeme in der Medizin, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland. 5. Klinik für Radiologie und Nuklearmedizin, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland. dominik.noerenberg@medma.uni-heidelberg.de.
Abstract
CLINICAL/METHODOLOGICAL ISSUE: Multiparametric magnetic resonance imaging (mpMRI) of the prostate plays a crucial role in the diagnosis and local staging of primary prostate cancer. STANDARD RADIOLOGICAL METHODS: Image-guided biopsy techniques such as MRI-ultrasound fusion not only allow guidance for targeted tissue sampling of index lesions for diagnostic confirmation, but also improve the detection of clinically significant prostate cancer. METHODOLOGICAL INNOVATIONS: Minimally invasive, focal therapies of localized prostate cancer complement the treatment spectrum, especially for low- and intermediate-risk patients. PERFORMANCE: In patients of low and intermediate risk, MR-guided, minimally invasive therapies could enable local tumor control, improved functional outcomes and possible subsequent therapy escalation. Further study results related to multimodal approaches and the application of artificial intelligence (AI) by machine and deep learning algorithms will help to leverage the full potential of focal therapies for prostate cancer in the upcoming era of precision medicine. ACHIEVEMENTS: Completion of ongoing randomized trials comparing each minimally invasive therapy approach with established whole-gland procedures is needed before minimally invasive therapies can be implemented into existing treatment guidelines. PRACTICAL RECOMMENDATIONS: This review article highlights minimally invasive therapies of prostate cancer and the key role of mpMRI for planning and conducting these therapies.
CLINICAL/METHODOLOGICAL ISSUE: Multiparametric magnetic resonance imaging (mpMRI) of the prostate plays a crucial role in the diagnosis and local staging of primary prostate cancer. STANDARD RADIOLOGICAL METHODS: Image-guided biopsy techniques such as MRI-ultrasound fusion not only allow guidance for targeted tissue sampling of index lesions for diagnostic confirmation, but also improve the detection of clinically significant prostate cancer. METHODOLOGICAL INNOVATIONS: Minimally invasive, focal therapies of localized prostate cancer complement the treatment spectrum, especially for low- and intermediate-risk patients. PERFORMANCE: In patients of low and intermediate risk, MR-guided, minimally invasive therapies could enable local tumor control, improved functional outcomes and possible subsequent therapy escalation. Further study results related to multimodal approaches and the application of artificial intelligence (AI) by machine and deep learning algorithms will help to leverage the full potential of focal therapies for prostate cancer in the upcoming era of precision medicine. ACHIEVEMENTS: Completion of ongoing randomized trials comparing each minimally invasive therapy approach with established whole-gland procedures is needed before minimally invasive therapies can be implemented into existing treatment guidelines. PRACTICAL RECOMMENDATIONS: This review article highlights minimally invasive therapies of prostate cancer and the key role of mpMRI for planning and conducting these therapies.
Authors: David Bird; Ann M Henry; David Sebag-Montefiore; David L Buckley; Bashar Al-Qaisieh; Richard Speight Journal: Int J Radiat Oncol Biol Phys Date: 2019-07-02 Impact factor: 7.038
Authors: David Bonekamp; M B Wolf; M C Roethke; S Pahernik; B A Hadaschik; G Hatiboglu; T H Kuru; I V Popeneciu; J L Chin; M Billia; J Relle; J Hafron; K R Nandalur; R M Staruch; M Burtnyk; M Hohenfellner; H-P Schlemmer Journal: Eur Radiol Date: 2018-06-25 Impact factor: 5.315
Authors: Willemien van den Bos; Berrend G Muller; Behfar Ehdaie; Peter Scardino; Jean J M C H de la Rosette Journal: Curr Opin Urol Date: 2014-05 Impact factor: 2.309
Authors: Simon R J Bott; Hashim U Ahmed; Richard G Hindley; Ahmad Abdul-Rahman; Alex Freeman; Mark Emberton Journal: BJU Int Date: 2010-12 Impact factor: 5.588
Authors: Willemien van den Bos; Matthijs J Scheltema; Amila R Siriwardana; Anton M F Kalsbeek; James E Thompson; Francis Ting; Maret Böhm; Anne-Maree Haynes; Ron Shnier; Warick Delprado; Phillip D Stricker Journal: BJU Int Date: 2017-09-04 Impact factor: 5.588
Authors: Lars Budäus; Jan Spethmann; Hendrik Isbarn; Jan Schmitges; Laura Beesch; Alexander Haese; Georg Salomon; Thorsten Schlomm; Margit Fisch; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber Journal: BJU Int Date: 2011-01-18 Impact factor: 5.588
Authors: Rajiv Chopra; Alexandra Colquhoun; Mathieu Burtnyk; William A N'djin; Ilya Kobelevskiy; Aaron Boyes; Kashif Siddiqui; Harry Foster; Linda Sugar; Masoom A Haider; Michael Bronskill; Laurence Klotz Journal: Radiology Date: 2012-08-28 Impact factor: 11.105
Authors: Irene A Burger; Julian Müller; Olivio F Donati; Daniela A Ferraro; Michael Messerli; Benedikt Kranzbühler; Edwin E G W Ter Voert; Urs J Muehlematter; Niels J Rupp; Ashkan Mortezavi; Daniel Eberli Journal: J Nucl Med Date: 2019-01-25 Impact factor: 10.057
Authors: Willemien van den Bos; Berrend G Muller; Hashim Ahmed; Chris H Bangma; Eric Barret; Sebastien Crouzet; Scott E Eggener; Inderbir S Gill; Steven Joniau; Gyoergy Kovacs; Sascha Pahernik; Jean J de la Rosette; Olivier Rouvière; Georg Salomon; John F Ward; Peter T Scardino Journal: Eur Urol Date: 2014-01-13 Impact factor: 20.096